A Study of SPY002-072 in Healthy Volunteers

NCT06622070 ↗

Phase 1 Recruiting 56 enrolled Spyre Therapeutics, Inc. Altasciences Company Inc. · collab

RandomizedSequentialQuadruple-blindBasic science

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

Timeline

Start: 2024-11-18
Primary completion: 2026-04-03
Completion: 2026-08-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPY002-072	Unknown	—	—

Indications

No indication recorded.